

### **IN THE SPECIFICATION**

In the specification, on page 10 after line 17, following the paragraph which reads :

“-- Brief Description of the Drawings

Fig. 1 shows a  $^{13}\text{C}$ -NMR spectrum of the product referred to as L<sub>11</sub>.

Fig. 2 shows a histogram showing the results of the first test of example 1.

Fig. 3 shows a histogram showing the results of the second test of example 1.

Fig. 4 shows a histogram showing the results of the third test of example 1 with I<sub>9</sub> concentrations of 0 mg/ml, 0.005 mg/ml, 0.01 mg/ml and 0.05 mg/ml.

Fig. 5 shows a histogram showing the results of the third test of example 1 with I<sub>9</sub> concentrations of 0 mg/ml, 0.1 mg/ml, 0.25 mg/ml and 0.5 mg/ml.

Fig. 6 shows a histogram showing the results of the third test of example 1 with I<sub>9</sub> concentrations of 0 mg/ml, 0.25 mg/ml, 0.5 mg/ml and 1 mg/ml.

Fig. 7 shows a histogram showing the results of the test of example 1 in which the active principle is added 3 hours after FasAb addition.

Fig. 8 shows a histogram showing the results of the test of example 1 in which the active principle is added 6 hours after FasAb addition.

Fig. 9 shows a histogram showing the results of the test of example 1 in which I<sub>9</sub> and staurosporin are added simultaneously.

Figs. 10-13 show a graph illustrating the results of the survival analysis of example 2.

Fig. 14 shows a graph illustrating the stimulation or inhibition of apoptosis caused by 0.2 mg/ml I<sub>9</sub>.

Fig. 15 shows a histogram showing the results of the test of example 4.---

#### **Please insert the following**

“---Fig. 16 shows a high pressure liquid chromatography (HPLC) profile of the product referred to as L<sub>11</sub>.---